SHPG - Shire plc

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
168.37
-0.76 (-0.45%)
As of 9:33AM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close169.13
Open168.54
Bid168.48 x 800
Ask168.52 x 800
Day's Range168.33 - 168.59
52 Week Range123.73 - 177.51
Volume14,194
Avg. Volume869,082
Market Cap53.56B
Beta1.42
PE Ratio (TTM)11.53
EPS (TTM)14.60
Earnings DateN/A
Forward Dividend & Yield1.05 (0.61%)
Ex-Dividend Date2018-03-08
1y Target Est201.82
Trade prices are not sourced from all markets
  • GlobeNewswire8 hours ago

    Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • GlobeNewswireyesterday

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • Shire, Shionogi File NDA for Intuniv for Adults in Japan
    Zacks2 days ago

    Shire, Shionogi File NDA for Intuniv for Adults in Japan

    Shire's (SHPG) Japanese partner Shionogi & Co., Ltd submits a new drug application for Intuniv in Japan for the treatment of attention deficit hyperactivity disorder (ADHD) in adults.

  • Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold
    Zacks2 days ago

    Amicus (FOLD) Gets FDA Nod for Fabry Disease Drug Galafold

    Amicus (FOLD) gets a major boost with the FDA approval of lead candidate, Galafold (migalastat) 123 mg capsules for the treatment of Fabry disease.

  • GlobeNewswire2 days ago

    New Drug Application Submitted in Japan for INTUNIV® (guanfacine hydrochloride extended release) in Adults with ADHD

    New Drug Application Submitted in Japan for INTUNIV ® in Adults with ADHD. Shire’ s partner, Shionogi, filed application to expand INTUNIV ® indication in Japan to include adults with ADHD Phase 3 clinical ...

  • GlobeNewswire5 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • GlobeNewswire6 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • GlobeNewswire7 days ago

    Shire plc: Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • GlobeNewswire8 days ago

    Shire plc : Director/PDMR Shareholding

    August 7, 2018– Shire plc. Notification of transactions by persons discharging managerial responsibilities. Oliver Strawbridge Senior Assistant Company Secretary.

  • GlobeNewswire8 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION.. ...

  • Thomson Reuters StreetEvents9 days ago

    Edited Transcript of SHP.L earnings conference call or presentation 31-Jul-18 1:00pm GMT

    Q2 2018 Shire PLC Earnings Call

  • GlobeNewswire13 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2
    Zacks14 days ago

    Shire's (SHPG) Earnings and Revenues Beat Estimates in Q2

    During the second quarter of 2018, the boards of Takeda and Shire (SHPG) reached an agreement pursuant to which the former will acquire the entire issued and to-be-issued ordinary share capital of the latter.

  • GlobeNewswire14 days ago

    Shire plc : Total voting rights

    Total Voting Rights August 1, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company"), in accordance with 5.6.1R of the Financial Conduct Authority`s (the "FCA") Disclosure Guidance ...

  • GlobeNewswire14 days ago

    Shire plc : Half-year Report

    Half-yearly Report August 1, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG), ("Shire" / the "Company"/ the "Group") in accordance with the Financial Conduct Authority`s Disclosure ...

  • GlobeNewswire14 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire15 days ago

    Shire plc : 2nd Quarter Results

      Shire Delivers Q2 2018 Product Sales Growth of 6% and Continued Regulatory and Pipeline Progress   Product sales grew to $3.8 billion driven by Immunology, recently launched products, and international ...

  • Associated Press15 days ago

    Shire: 2Q Earnings Snapshot

    The Dublin-based company said it had net income of $2.01 per share. Earnings, adjusted for one-time gains and costs, were $3.88 per share. The results beat Wall Street expectations. The average estimate ...

  • Shire profit edges higher ahead of Takeda sale
    Reuters15 days ago

    Shire profit edges higher ahead of Takeda sale

    Shire (SHP.L), the London-listed pharmaceutical group being bought by Japan's Takeda , reported a 4 percent rise in second-quarter earnings as revenue rose 5 percent to $3.92 billion, just ahead of market expectations. Earlier on Tuesday, Takeda said its first-quarter operating profit had halved from a year ago, when it had booked gains from asset sales. It is buying Shire to broaden its drugs portfolio and plug a gap in its late-stage pipeline.

  • GlobeNewswire16 days ago

    Shire plc : Miscellaneous

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire20 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...

  • GlobeNewswire21 days ago

    Shire plc : Director Declaration

    Director Declaration July 25, 2018 - Shire plc (LSE: SHP, NASDAQ: SHPG) (the "Company") announces that Steven Gillis, Non-Executive Director of the Company, is a Non-Executive Director of Homology ...

  • GlobeNewswire21 days ago

    Shire plc : Rule 2.9 Announcement

    NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION. ...